# Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® Molecule

> **NCT06812988** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Sanofi** · enrollment: 84 (estimated)

## Conditions studied

- Type 1 Diabetes Mellitus

## Interventions

- **DRUG:** Brivekimig
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06812988
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-02-28
- **Primary completion:** 2027-04-29
- **Final completion:** 2027-04-29
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2026-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06812988

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06812988, "Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® Molecule". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT06812988. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*